- Home
- AGFY vs RAPT Comparison
AGFY vs RAPT Comparison
Compare AGFY & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGFY
- RAPT
- Stock Information
- Founded
- AGFY 2016
- RAPT 2015
- Country
- AGFY United States
- RAPT United States
- Employees
- AGFY N/A
- RAPT N/A
- Industry
- AGFY Military/Government/Technical
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- AGFY Consumer Discretionary
- RAPT Health Care
- Exchange
- AGFY Nasdaq
- RAPT Nasdaq
- Market Cap
- AGFY 73.0M
- RAPT 59.1M
- IPO Year
- AGFY 2021
- RAPT 2019
- Fundamental
- Price
- AGFY $20.95
- RAPT $1.18
- Analyst Decision
- AGFY
- RAPT Hold
- Analyst Count
- AGFY 0
- RAPT 10
- Target Price
- AGFY N/A
- RAPT $6.00
- AVG Volume (30 Days)
- AGFY 40.6K
- RAPT 2.2M
- Earning Date
- AGFY 11-14-2024
- RAPT 03-06-2025
- Dividend Yield
- AGFY N/A
- RAPT N/A
- EPS Growth
- AGFY N/A
- RAPT N/A
- EPS
- AGFY N/A
- RAPT N/A
- Revenue
- AGFY $10,385,000.00
- RAPT N/A
- Revenue This Year
- AGFY $468.67
- RAPT N/A
- Revenue Next Year
- AGFY N/A
- RAPT N/A
- P/E Ratio
- AGFY N/A
- RAPT N/A
- Revenue Growth
- AGFY N/A
- RAPT N/A
- 52 Week Low
- AGFY $2.71
- RAPT $0.79
- 52 Week High
- AGFY $84.44
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- AGFY 37.71
- RAPT 43.24
- Support Level
- AGFY $22.29
- RAPT $1.07
- Resistance Level
- AGFY $27.99
- RAPT $1.28
- Average True Range (ATR)
- AGFY 2.71
- RAPT 0.14
- MACD
- AGFY -0.76
- RAPT -0.03
- Stochastic Oscillator
- AGFY 3.32
- RAPT 16.11
About AGFY Agrify Corporation
Agrify Corp is a leading provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. Its proprietary micro-environment-controlled Agrify Vertical Farming Units (VFUs) enable cultivators to produce high-quality products The products offered by the company include Integrated Grow Racks, LED Grow Lights, Hydroponics, and Vertical Farming Units.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.